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AbstrAct
Objective Explore the cost-effectiveness of lifestyle 
interventions and metformin in reducing subsequent 
incidence of type 2 diabetes, both alone and in 
combination with a screening programme to identify high-
risk individuals.
Design Systematic review of economic evaluations.
Data sources and eligibility criteria Database searches 
(Embase, Medline, PreMedline, NHS EED) and citation 
tracking identified economic evaluations of lifestyle 
interventions or metformin alone or in combination with 
screening programmes in people at high risk of developing 
diabetes. The International Society for Pharmaco-
economics and Outcomes Research’s Questionnaire to 
Assess Relevance and Credibility of Modelling Studies for 
Informing Healthcare Decision Making was used to assess 
study quality.
results 27 studies were included; all had evaluated 
lifestyle interventions and 12 also evaluated metformin. 
Primary studies exhibited considerable heterogeneity 
in definitions of pre-diabetes and intensity and duration 
of lifestyle programmes. Lifestyle programmes and 
metformin appeared to be cost effective in preventing 
diabetes in high-risk individuals (median incremental 
cost-effectiveness ratios of £7490/quality-adjusted life-
year (QALY) and £8428/QALY, respectively) but economic 
estimates varied widely between studies. Intervention-only 
programmes were in general more cost effective than 
programmes that also included a screening component. 
The longer the period evaluated, the more cost-effective 
interventions appeared. In the few studies that evaluated 
other economic considerations, budget impact of 
prevention programmes was moderate (0.13%–0.2% of 
total healthcare budget), financial payoffs were delayed 
(by 9–14 years) and impact on incident cases of diabetes 
was limited (0.1%–1.6% reduction). There was insufficient 
evidence to answer the question of (1) whether lifestyle 
programmes are more cost effective than metformin or (2) 
whether low-intensity lifestyle interventions are more cost 
effective than the more intensive lifestyle programmes that 
were tested in trials.
conclusions The economics of preventing diabetes are 
complex. There is some evidence that diabetes prevention 
programmes are cost effective, but the evidence base 
to date provides few clear answers regarding design 
of prevention programmes because of differences in 
denominator populations, definitions, interventions and 
modelling assumptions.
IntrODuctIOn
Diabetes is a global health priority, with 
415 million known adult cases worldwide, of 
which 91% are type 2 diabetes.1 Ageing of 
the population is predicted to drive substan-
tial increases in prevalence (estimated to 
642 million by 2040),2 with particularly 
rapid increases in low-and-middle-income 
countries.3 The burden of complications 
in diabetes is high, including heart disease, 
stroke, neuropathy, nephropathy and reti-
nopathy.4 Type 2 diabetes develops as a result 
of genetic, environmental and behavioural 
factors, including sedentary lifestyle and 
energy-rich, nutrient-poor diet, both of which 
predispose to obesity.5
Diabetes takes a significant toll on health 
budgets around the world, accounting for 
5%–20% of total healthcare expenditure 
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strengths and limitations of this study
 ► To our knowledge, this is the largest and most up-to-
date summary of economic evaluations of diabetes 
prevention programmes and the only one to include 
comparison with metformin and consideration 
of relevance and credibility for policymakers. We 
undertook a detailed analysis of assumptions 
underpinning modelling studies and compared 
these with findings from clinical trials.
 ► Limitations are the small number of economic 
evaluations included that reflect prevailing national 
policy and the preponderance of studies from 
wealthy developed countries.
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in many countries.1 Both absolute costs and proportion 
of overall health budget for type 2 diabetes are set to 
increase further in future decades as prevalence rises, in 
the context of a marked reduction in the proportion of 
the population who are economically active (eg, in the 
UK, the relative economic burden per worker is expected 
to increase by 40%–50% by 20606). Cost-effective treat-
ment and prevention strategies, with acceptable budget 
impact, will therefore become increasingly important as 
resources become stretched.
types of pre-diabetes
Type 2 diabetes is often preceded by a phase of abnormal 
glucose regulation (pre-diabetes). Pre-diabetes is a 
generic term that includes impaired fasting glucose 
(IFG), impaired glucose tolerance (IGT) and HbA1c in 
the ‘at risk’ range.7 One individual may have one, two or 
all of these types of pre-diabetes. Table 1 describes these 
different pre-diabetic states, how they are diagnosed and 
current diagnostic guidelines.8–10 The distinction between 
types of pre-diabetes is important for a number of reasons. 
First, different definitions of pre-diabetes are associated 
with distinct physiological changes. IFG is associated 
with reduced hepatic insulin sensitivity and first-phase 
insulin response; IGT is associated with reduced periph-
eral insulin sensitivity and second-phase insulin response 
and HbA1c reflects aggregated blood glucose levels over 
time.11 Second, progression to diabetes ranges from 3.6% 
to 7.0% annually depending on the type of pre-diabetes.12 
Third, IGT is associated with increased risk of microvas-
cular disease, whereas the relationship is less clear for 
other types of pre-diabetes.7 Finally, there is evidence that 
people with different types of pre-diabetes respond differ-
ently to the same intervention. For example, in a large 
US trial, the US Diabetes Prevention Program (USDPP), 
lifestyle programmes were less effective and metformin 
more effective in participants with IGT, IFG and HbA1c in 
the ‘at-risk range’ compared with the entire cohort which 
were identified on the basis of IGT and IFG.13
types of screening and prevention programmes
Pre-diabetes is almost always asymptomatic. It tends to be 
diagnosed incidentally (when blood tests are performed 
for other reasons) or as part of a proactive screening 
programme delivered either to an entire population or 
to selected individuals. Most commonly, screening blood 
tests are offered to people identified as at high risk of 
developing diabetes based on demographic variables 
(eg, age, ethnicity), survey questions (eg, family history 
of diabetes, personal history of gestational diabetes) or 
biomarkers (eg, body mass index (BMI), blood pressure), 
typically combined in a ‘diabetes risk score’.14 People 
diagnosed with pre-diabetes may be offered a lifestyle 
programme (to encourage a healthy diet and increased 
physical activity) or metformin. These interventions have 
been shown to delay or prevent type 2 diabetes in a signifi-
cant proportion of participants in large randomised trials 
in the USA,15 Europe,16 China17 and India.18 Lifestyle 
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programmes in these trials were intensive and sustained: 
3–10 years of individual and group sessions provided by 
specialist staff (dieticians or exercise physiologists with 
annual physician review). Subsequent translation of these 
findings into large-scale community-based programmes 
produced interventions that were both shorter (3–12 
months) and less intense (eg, they offered less sessions 
and were delivered to groups rather than individuals 
by non-specialist staff such as lay workers or preven-
tion managers). These large-scale community-based 
programmes have been offered to populations of similar 
age and BMI to the large trials but with different selection 
criteria (eg, selection based on elements of the metabolic 
syndrome rather than the criteria of IGT seen in the large 
trials).19 There is some evidence that these pragmatic 
interventions offered to a real-world population deliver 
more limited and less sustained benefits than were seen 
with more intensive interventions in trial populations.20
Given the potential impact on populations and health 
budgets, the burden of type 2 diabetes is a key issue for poli-
cymakers. In response, a number of countries, including 
the USA and the UK, are developing (or seeking to 
develop) national diabetes prevention programmes.21 22 
The design of large-scale prevention programmes incor-
porates a number of important choices: (1) whether to 
screen a portion of the population for diabetes risk or 
focus on people who are already known to have pre-di-
abetes; (2) if no screening programme is in place, how 
to identify participants who may benefit from a diabetes 
prevention programme; (3) the role of different types 
of interventions (lifestyle programmes or metformin) 
and (4) the optimum intensity and duration of the 
programme.
This study was designed to help inform decision-making 
by local and national policymakers and health insurers in 
countries with a high and/or rising incidence of type 2 
diabetes. Our research question were
1. What is the evidence on cost-effectiveness of lifestyle 
programmes or metformin in diabetes prevention?
2. What is the impact of the following factors on the 
cost-effectiveness of these interventions?
a. Type of pre-diabetes (IFG, IGT or ‘at risk’ HbA1c).
b. Intensity of lifestyle intervention: Including three 
different measures of intensity, each of which was 
examined separately: (i) frequency of contact in 
initial ‘core’ teaching/coaching sessions, (ii) du-
ration of core and maintenance intervention and 
(iii) group or individual format of sessions.
c. Inclusion of screening: Intervention-only studies 
on a predefined pre-diabetic or high-risk popula-
tion or screening for pre-diabetes followed by in-
tervention.
d. Years of follow-up to evaluate diabetes incidence: 
<10 years and ≥25 years.
3. What are the implications of these findings for 
policymakers and health insurers?
A number of systematic reviews of economic evalu-
ations of diet and exercise in diabetes prevention have 
been undertaken in the last 10 years.23–27 This paper 
is the first review to consider the cost-effectiveness of 
metformin and the first review to examine interven-
tion-only and screening-plus-intervention studies sepa-
rately. In addition, this paper adds to previous reviews 
by updating the data set with two new primary studies 
not included in previous systematic reviews28 29 and eval-
uating studies’ relevance for decision-making by policy-
makers and health insurers.
MethODs
search strategy and inclusion criteria
A database search (covering Embase, PreMedline, 
Medline and NHS EED) for peer-reviewed articles on 
pre-diabetes and diabetes prevention between 2004 
(the year before the publication of the first cost-effec-
tiveness review of the USDPP) and 2014 identified 3833 
papers. Search terms are outlined in online supple-
mentary appendix 1. Citation tracking and screening 
of references (in included studies and review articles) 
identified a further 23 papers up to April 2016. Dupli-
cates were removed and abstracts screened by two 
reviewers (EB, SR). We included studies that reported 
full economic evaluation (cost-effectiveness, cost-utility 
or cost-benefit analysis) of (1) lifestyle programmes, (2) 
metformin or (3) screening in combination with life-
style programmes and/or metformin against a base case 
of usual care or no intervention.
To meet our inclusion criteria, economic evaluations 
needed to have
1. evaluated the treatment of pre-diabetes with either 
metformin and/or lifestyle programmes (that 
addressed diet and physical activity);
2. included ≥12 months of intervention and follow-up;
3. quantified outcomes (such as change in quality-ad-
justed life-years (QALYs), disability-adjusted life-years 
(DALYs), life-years gained (LYG) or numbers needed 
to treat to prevent one case of type 2 diabetes);
4. described the method used to classify people as high 
risk of developing type 2 diabetes (hence eligible for 
interventions), including: blood tests for pre-diabetes 
(any in table 1), screening questionnaires, diabetes 
risk algorithms or presence of particular risk factors.
Review articles were excluded as were articles focusing 
only on women with a history of gestational diabetes.
Full papers meeting the above criteria were reviewed; 
data were extracted from included papers (by SR) and 
data extraction for a third of papers was checked by a 
second reviewer (EB).
Quality assessment
A checklist developed by the International Society for 
Pharmaco-economics and Outcomes Research (the 
ISPOR-AMCP-NCP questionnaire30) was used to eval-
uate the relevance and credibility of modelling studies 
for decision-making by policymakers.
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box Definitions of measures of effectiveness used in 
included studies93 94
Quality-adjusted life-year (QALY)
A measure of the state of health of a person or group in which the 
benefits, in terms of length of life, are adjusted to reflect the quality of 
life. One QALY is equal to 1 year of life in perfect health.
Disability-adjusted life-year
A measure of the impact of a disease or injury in terms of healthy 
years lost.
Life-years gained
A measure of the impact of a disease or treatment on the length of life. 
Years of life are not adjusted to reflect health or disability.
Assumptions and calculations
All the economic evaluations included in this review were 
cost-effectiveness analyses (including cost-utility analyses), 
which measure both the cost of the intervention and the 
impact of the intervention on participants’ quality and/
or length of life.31 No full cost-benefit analyses were iden-
tified. Cost-effectiveness analyses report their results as 
ratios of incremental costs divided by incremental bene-
fits; in an incremental cost-effectiveness ratio (ICER). 
Resources to spend on healthcare are finite, so policy-
makers set a ‘willingness-to-pay’ threshold against which a 
treatment’s ICER is compared. Historically, the National 
Institute for Health and Care Excellence (NICE) in the 
UK has approved new technologies below the willing-
ness-to-pay threshold of £20 000–£30 000/QALY,32 the 
USA has used a threshold of $50 000/QALY33 and WHO 
has recommended cost less than the per capita gross 
domestic product of the relevant country per DALY as the 
threshold.34 For this review, we used a willingness-to-pay 
threshold of £20 000/QALY. This means that if an inter-
vention is below the willingness-to-pay threshold (costs 
<£20 000 per QALY), the intervention is considered cost 
effective. If the intervention costs more than the willing-
ness-to-pay threshold, it is considered not cost effective. 
An intervention is only cost saving if it is more effective 
and costs less than current treatment.
Costs are reported in British pounds 2015 using 
purchasing power parity and currency exchange rates 
from the CCEMG-EPPI-Centre Cost Converter.35 Costs 
of lifestyle interventions were calculated in 2015 British 
pounds where sufficient data were available on constit-
uent activities and staff involved, drawing on the Personal 
Social Services Research Unit36 for UK staff cost estimates.
ICERs are reported separately for each outcome 
measure: as either cost saving or £/QALY gained (£/
QALY), £/DALY averted (£/DALY) or £/life-year gained 
(£/LYG) (box).
ICERs are reported from two different perspectives: 
health system and societal perspective. The health system 
perspective includes only direct medical costs such as 
(1) staff, facilities, medication and consumables costs 
required for provision of the intervention; and (2) general 
healthcare of participants. In addition, studies of cost-ef-
fectiveness from a societal perspective include some or 
all elements of (1) indirect costs of the intervention (eg, 
exercise equipment, food preparation equipment), (2) 
participant time (travelling to and participating in inter-
vention’s activities), (3) lost productivity due to absence 
from work and (4) disability benefits payments.
Studies were grouped on a number of dimensions to 
identify key drivers of differences through subgroup 
analysis. Subgroups examined included: type of pre-di-
abetes, intensity of lifestyle intervention (defined by 
number of sessions in ‘core’ intervention, duration of 
core and maintenance programme, group vs individual 
format), inclusion of screening and years of follow-up 
to evaluate diabetes incidence. Subgroup medians could 
not be derived for the type of pre-diabetes as the majority 
of studies used IGT to identify eligible participants (with 
or without IFG), and there were two or less studies that 
reported £/QALY using each of the remaining methods 
of identification. Therefore, in order to understand 
the potential significance of the type of pre-diabetes 
we undertook a meta-analysis of randomised controlled 
trials of lifestyle programmes for diabetes prevention. 
Data were extracted from the 22 primary studies that 
reported diabetes incidence as an end point that were 
included in three recent systematic reviews of lifestyle 
programmes in diabetes prevention.37–39 Data were 
analysed in RevMan V.5.3. Due to the heterogeneity of 
the primary studies, we used a random-effects model 
and analysed subgroups defined by the trials’ inclusion 
criteria (IFG, IGT, HbA1c or risk score) and duration 
of the intervention. Forest plots were generated to illus-
trate the relative risk of diabetes following a lifestyle 
programme for each of these groups compared with no 
intervention.
Patient and public involvement
This review was conceptualised by a multidisciplinary 
group, including lay members, in Newham, East London. 
The authors attended regular project meetings of this 
group, reporting back the results of the review to the rest 
of the team.
resuLts
In total, 42 full papers were reviewed and 15 were 
excluded for reasons outlined in figure 1.
In total, 27 studies of diabetes prevention programmes 
with economic evaluations have been published from 
15 countries between 2004 and 2016.28 29 40–64 Six of the 
economic evaluations were within-trial cost-utility anal-
yses and 21 were modelling studies (16 Markov models, 
2 simulation models, 2 decision trees and 1 combination 
Markov model and decision tree). Within the model-
ling studies there were a wide range of model structures, 
parameters and parameter values which in part drive the 
variability observed in study results.65
group.bmj.com on December 28, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
 5Roberts S, et al. BMJ Open 2017;7:e017184. doi:10.1136/bmjopen-2017-017184
Open Access
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow diagram.
type of intervention
All 27 studies evaluated lifestyle interventions and 12 also 
evaluated metformin (online supplementary appendix 
2). Thirteen reported interventions in a population previ-
ously identified as pre-diabetic (people with IFG, IGT or 
high HbA1c) and 14 reported screening of a broader 
population and subsequent intervention on those identi-
fied as high risk of developing type 2 diabetes. The majority 
of studies evaluated intensive trial-based interventions, 
although there was a great deal of heterogeneity in the 
type of lifestyle interventions evaluated. Table 2 describes 
some of the dimensions on which lifestyle programmes 
differed: frequency of contact, duration, staff providing 
intervention, individual versus group interventions and 
frequency of contact.
Three studies45 54 59 did not specify the details of their 
lifestyle interventions.
Intensive trial-based lifestyle programmes
In total, 18 of the 24 studies that did describe in detail 
the lifestyle intervention being evaluated were based on 
intensive trial-based lifestyle interventions (8 based on the 
USDPP, 4 on the USDPP together with the US Diabetes 
Prevention Program Outcome Study, 3 on the Finnish 
Diabetes Prevention Study, 1 on the Da Qing study, 1 on 
the Indian Diabetes Prevention Programme and 1 on 
DE-PLAN-CAT). The primary studies were generously 
resourced, large (300–3000 participants) and provided 
lengthy interventions (3–10-year duration) including 
7–16 initial contacts in the ‘core programme’ delivered 
by specialist staff (dieticians, exercise physiologists and 
annual medical review). Two within-trial studies40 64 
reported intensive trial-based lifestyle programme costs in 
sufficient detail for costs to be reconstituted on an activ-
ity-based costing basis (online supplementary appendix 
3). The costs in 2015 British pounds of these interven-
tions were as follows: £2915 per participant over 3 years 
for the USDPP lifestyle programme, £4001 per partici-
pant over 3 years for the Indian DPP lifestyle programme 
(excluding staff travel costs).
Translational community-based programmes
In total, 3 of the 24 studies were based on community 
translation of these intensive interventions lasting 3–5 
years and 3 studies were based on other published 
studies covering much smaller populations (<150 
participants) and providing less intensive interventions 
(ranging from 12 weeks to 1 year in duration), delivered 
by non-specialist staff (diabetes prevention facilitators 
and lay workers).
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target population: demographics and type of pre-diabetes
The target population for 16 of the 27 studies were 
overweight individuals with IGT, with or without IFG. 
Four used IFG alone,42 52 56 63 two used IGT or IFG,44 51 
one used IFG or HbA1c,53 one used HbA1c alone29 and 
three used other methods of screening (such as diabetes 
risk algorithms, BMI or other elements of metabolic 
syndrome).41 43 45 Also, 17 out of 27 studies included 
participants based on a BMI ≥24 kg/m2, 3 included partic-
ipants based on a BMI ≥30 mg/kg2 and the remainder did 
not state a BMI cut-off for participation. A wide range of 
ages (from 18 years and older) were included.
benefits of interventions
The primary benefit of diabetes prevention programmes 
is reduction in incidence of type 2 diabetes and its associ-
ated complications, measured in the number needed to 
treat to delay or prevent a case of diabetes or improve-
ments in QALYs, DALYs and LYG, as summarised in 
online supplementary appendix 4.
Lifestyle interventions
In total, 21 studies reported change in QALYs associated 
with lifestyle interventions with a median 0.159 (range: 
0.003–2.91) increase in QALYs and 13 reported LYG with 
a median increase of 0.30 (range: 0.04–0.84) increase 
relative to usual care. Four studies reported numbers 
needed to treat with lifestyle programmes to prevent one 
case of type 2 diabetes with results ranging from 4.2 to 30.
Metformin
Eight studies measured change in QALYs associated with 
metformin therapy with a median of 0.105 (range: 0.01–
2.83) increase in QALYs and five studies reported increase 
in LYG with a median gain of 0.14 (range: 0.05–0.3). Two 
studies reported number needed to treat with metformin 
to prevent 1 case of type 2 diabetes as 6.9 and 27.9.
Side effects of screening or intervention
The impact of screening and intervention on length of 
quality of life was included as a change in incremental 
QALYs in a number of studies,49–51 and three studies 
modelled the impact of adverse effects explicitly.40 47 57
Value for money
Policymakers may consider a range of economic factors 
when considering a new programme: cost-effectiveness, 
budget impact, effect on incident cases of the disease and 
equity of healthcare provision.66 All studies included in 
this review considered cost-effectiveness, reporting ICERs, 
five described budget impact, two modelled impact on 
incident cases of diabetes and none considered impact 
on equity of healthcare provision.
Cost-effectiveness
Overall, lifestyle interventions and metformin appeared 
to be cost effective in preventing diabetes in high-risk 
individuals, as summarised in table 3, though there was 
wide variation in economic estimates between studies. 
Substantial differences in participant selection and 
intervention design, which reflect the different types of 
pre-diabetes and different types of interventions, as well 
as differences in model structure, parameters and param-
eter values, make comparison between studies difficult.
There is insufficient evidence to suggest that lifestyle 
interventions or metformin will be cost saving. Out of 27 
studies, lifestyle interventions were found to be cost saving 
in 2 studies from a health system perspective,53 57 cost 
saving from a health system perspective in some countries 
but not others in one study47 and cost saving from a soci-
etal perspective in three studies.52 56 62 Of the 12 studies 
evaluating metformin, 2 studies concluded metformin 
was cost saving from a health system perspective,40 46 1 
study concluded metformin was cost saving from a health 
system perspective in some countries but not others47 and 
2 concluded metformin was cost saving from a societal 
perspective.40 61
Lifestyle programmes appear to be cost effective. Of 
the 16 studies measuring cost-effectiveness as £/QALY, 
the median ICER from a health system perspective was 
£7490/QALY (range: cost saving to £134 420/QALY). 
Only two studies reported lifestyle interventions that were 
not cost effective (costing >£20 000 per QALY); of these, 
one used a model substantially different in structure 
to other modelling studies included (the Archimedes 
model, which analyses changes in biological variables, 
such as insulin resistance, rather than transitions between 
disease states, such as pre-diabetes, which are used by 
other models)48 and the other included analysis lasting 
only 1 year; therefore, the benefits of reduced incidence 
of diabetes were not included.42
Metformin also appears to be cost effective from a 
health system perspective. Of the seven studies measuring 
cost-effectiveness as £/QALY, the median ICER from 
a health system perspective was £8428/QALY (range: 
cost saving to £32 430/QALY). Two studies reported 
metformin to not be cost effective (costing >£20 000 
per QALY): of these, one used a model substantially 
different in structure to other modelling studies included 
(the Archimedes model)48 and the other was the first 
economic model of the USDPP.49 The subsequent models 
based on the USDPP and its follow-up study have found 
metformin to be cost saving or cost effective.40
Twelve studies compared lifestyle programmes and 
metformin directly. From a health system perspective, 
neither intervention appears more cost effective than 
the other with six studies reporting lifestyle programmes 
more cost effective than metformin,46 49 54 57 58 60 five 
studies29 40 43 47 55 reporting metformin more cost effective 
than lifestyle programmes and one62 showing <1% differ-
ence in cost-effectiveness between the two. However, 
from a societal perspective, metformin appears more 
cost effective than lifestyle programmes, with four40 48 58 62 
out of the five studies undertaking this analysis finding 
metformin more cost effective. This is because the cost 
of participants’ time travelling to and attending lifestyle 
programme sessions is included in most calculations of 
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cost from a societal perspective, but not from a health 
system perspective.
Given the range of screening and lifestyle interven-
tions provided, and the range of cost-effectiveness ratios, 
studies which reported ICERs as £/QALY from a health 
system perspective were grouped on a number of dimen-
sions to identify key drivers of differences. The analyses 
revealed that:
1. Screening plus intervention studies tended to be less 
cost effective than intervention-only studies on average, 
but both approaches were associated with a wide 
range of ICERs highlighting current uncertainties. Of 
the 10 studies that reported £/QALY from a health 
system perspective for intervention-only studies, the 
median ICER was £4606/QALY (range: cost saving to 
£134 420/QALY). And the median ICER for the eight 
screening-plus-intervention studies was £7814/QALY 
(range: £573 –76 566/QALY).
2. In general, the longer the period evaluated the more 
cost effective the interventions appeared. Studies that 
measured cost-effectiveness over a period of ≥25 years 
appeared more cost effective (median ICER: £2976/
QALY) than studies that measured cost-effectiveness 
over ≤10 years (median ICER: £10 416).
3. There was insufficient evidence to conclude whether 
lifestyle programmes with a duration of <2 years, 2–6 
years or >6 years were more or less cost effective: Of 
the nine studies that included lifestyle programmes 
with a duration of >2 years and <6 years, the medi-
an ICER was £3275/QALY (range: cost saving to £134 
420/QALY). Three studies included interventions <2 
years duration with a wide variety of results (ICERs 
of £3215 [43], £10 471 [45] and £76 566 [44]). And 
three reported interventions of >6 years duration with 
a median ICER of £7628/QALY (range: cost saving to 
£15 191/QALY).
4. There was insufficient evidence to conclude whether 
higher frequency of contact during ‘core sessions’ was 
more or less cost effective: Of the 11 studies that in-
cluded lifestyle programmes with ≥16 core sessions, 
the median ICER was £7628/QALY (range: cost sav-
ing to £134 420/QALY). Three studies reported £/
QALYs for lifestyle programmes with <16 core sessions 
with widely varying results (ICERs of £3215 [43], 
£3275 [46] and £76 566 [44]).
5. There was insufficient evidence to conclude whether 
group or individual core sessions were more or less 
cost effective: Of the 11 studies that included the core 
component of the lifestyle programme delivered on 
an individual basis, the median ICER was £7628/
QALY (range: cost saving to £134 420/QALY). Three 
studies included lifestyle programmes where the core 
component was delivered in groups with a wide range 
of results (ICERs of £6214 [55], £3215 [43], £3275 
[46] and £76 566 [44]).
There were insufficient studies in each group to 
conduct cost-effectiveness subgroup analysis by type of 
pre-diabetes. However, our meta-analysis of intervention 
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Figure 2 Lifestyle programme’s effect on diabetes incidence.15–18 67–86 IFG, impaired fasting glucose; IGT, impaired glucose 
tolerance.
trials suggests that this may be an important factor. 
Meta-analysis of intervention trials15–18 66–86 (figure 2) 
showed that lifestyle interventions ≥3 years duration 
for participants with IGT reduced the relative risk of 
developing diabetes by 45% (95% CI 28% to 57%). 
Lifestyle interventions lasting <3 years in participants 
with IGT showed a 26% (95% CIs 0% to 45%) relative 
risk reduction. There were insufficient studies to divide 
participants identified by other diagnostic criteria by 
duration of intervention. But for all studies that identi-
fied participants by IFG alone, IFG or IGT and presence 
of risk factors, the relative risk of diabetes was reduced 
by 37% (95% CI 12% to 55%), 23% (95% CI 5% to 
38%) and 11% (95% CI −0.2% to 22%), respectively. No 
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studies used HbA1c alone as the diagnostic criteria for 
selecting participants.
Other measures impacting the ‘value for money’ judgement
Cost-effectiveness analysis only measures cost and benefit of 
an intervention for an individual participant. Policymakers, 
who are responsible for overall health budgets and the 
health of the population as a whole, may consider other 
measures (such as budget impact, impact on equity and 
impact on incident cases of the disease) when evaluating 
the impact of an intervention. In terms of budget impact, 
three studies45 59 60 estimated the cost of implementing a 
national diabetes prevention programme to be between 
0.13% and 0.2% of annual national health expenditure in 
the Netherlands, Germany and Australia. Two studies53 59 
modelled annual expenditures for lifestyle programmes, 
showing that net savings only exceeded net expenditures 
9–14 years after initiating the prevention programme.
Failure to attend screening, enrol in an intervention or 
comply with an intervention means that the number of 
cases of diabetes prevented is lower than might be antici-
pated when extrapolating from trials. As a result of these 
factors, as well as the partial and finite impact of interven-
tions, two studies45 60 estimated that only 0.1%–1.6% of 
cases of diabetes would be prevented by a population-wide 
programme in the Netherlands and a region of Germany. 
As an example of how this population-wide impact is 
calculated, Icks60 calculated that 29% of incident cases of 
diabetes in 3 years would be due to people with pre-dia-
betes (defined as IGT in this study). Of this pre-diabetic 
population, 30% of people would attend the screening test 
(oral glucose tolerance test (OGTT)), 40% and 59% would 
participate in the lifestyle intervention and metformin, 
respectively. In total, 32% of these would develop diabetes 
in 3 years with no intervention and 9.3% and 28.8% would 
develop diabetes with lifestyle and metformin respectively 
which resulted in 0.2% of incident cases of diabetes being 
prevented by metformin and 0.8% by lifestyle programmes. 
These rates of attendance and enrolment are based on 
best estimates, a recent systematic review found significant 
variation in participation rates seen in studies of lifestyle 
programmes.87
Quality, relevance/applicability and credibility of existing 
economic evaluations for current healthcare decision-making
Evaluation of studies against ISPOR’s Questionnaire to 
Assess Relevance and Credibility of Modelling studies for 
Healthcare Decision Making30 (online supplementary 
appendix 5) raised a number of issues. The most important 
of these for policymakers are outlined below. No studies 
were excluded on the basis of this evaluation.
Relevance/applicability of included studies (table 4)
Given the variety of lifestyle programmes and range of 
different types of pre-diabetes, we examined the extent to 
which the included studies reflect national guidance in the 
UK88 89 and the USA,9 21 and the areas in which they differ.
Health system context
In total, 24 out of 27 studies were undertaken in high-in-
come, predominantly Caucasian nations. Only two 
studies62 64 were undertaken in developing countries, 
China and India.
Target population
Only 629 42 52 53 56 63 out of 27 studies used diagnostic tests 
for pre-diabetes that are in line with current UK guidance, 
that is, HbA1c or fasting plasma glucose. The majority of 
studies, 16 out of 27, included participants with a positive 
oral glucose tolerance test (with or without fasting blood 
glucose). Prevalence differs between different types of 
pre-diabetes, with the potential to have a large impact on 
budgets. For example, one study in this review51 compared 
the cost-effectiveness of different diagnostic tests and found 
that expanding the definition of pre-diabetes from IGT and 
IFG to IFG or IGT increased the number of eligible partic-
ipants threefold, with the savings from reduced diabetes 
incidence insufficient to offset the increase in cost, with a 
resulting small reduction in cost-effectiveness.
Type of intervention
In total, 21 of the 27 studies evaluated intensive trial-based 
interventions or intensive translations of trial interventions, 
which reflect current ADA guidance (lifestyle interventions 
modelled on the USDPP, targeting 7% wt loss).9 However, 
reviews of community translations of the USDPP trial 
showed that while these translational programmes cost less 
to implement they were also less effective.19 20 The model-
ling studies based on the USDPP trial data may therefore 
not be relevant comparators for a USDPP-based community 
programme. In contrast, NICE in the UK and the Commu-
nity Preventative Services Task Force in the USA advocate 
a more pragmatic approach to lifestyle programmes. Only 
three studies41–43 in this review are relevant comparators 
in terms of duration and intensity of lifestyle intervention 
and they report a wide range of cost-effectiveness (from 
£3215/QALY to £76 566/QALY). One study42 (ICER £76 
566) was an in-trial cost-utility analysis over 1 year, there-
fore was unable to quantify the impact of the prevention 
programme on diabetes incidence. And one41 assumed 
treatment effects equivalent to those seen in a trial of an 
intensive lifestyle programme.
Credibility of included studies
Two key issues emerged with the assessment of the cred-
ibility of the modelling studies included in this review: 
(1) areas where updated evidence is available that may 
impact the evaluation and (2) areas where uncertainty 
persists and a range of assumptions are observed.
Availability of updated meta-analyses
In total, 12 of the 21 modelling studies assumed reduc-
tions in diabetes incidence equivalent to that achieved in 
the USDPP or Finnish Diabetes Prevention Study trials 
(relative risks of 0.50 at 3 years and 0.40 at 6 years respec-
tively). However, two recent meta-analyses of randomised 
controlled trials37 38 have shown a relative risk of diabetes 
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Table 4 Relevance of included studies (numbers refer to the number of studies in this review in each category)
Health system context
USA UK Europe Australia Canada Singapore India China
Which health 
system?
9 3 8 3 2 1 1 1
Target population
IGT (± IFG) IFG IFG or IGT HbA1c
Other (eg, risk 
score)
Current 
guidance
Which diagnostic 
test for pre-
diabetes?
16 5 2 2 3 UK: IFG or 
HbA1c for 
diagnosis
ADA: IFG, IGT 
or HbA1c for 
diagnosis
Type of intervention/s evaluated
Trial-based lifestyle 
programme
Pragmatic lifestyle 
programme
Not 
stated Current guidance
Trial-based 
lifestyle or 
pragmatic 
lifestyle?
18 trial based
3 translations of trials
3 3 UK: Pragmatic lifestyle programmes—Group lifestyle 
programme with 16 hours of contact time over 
9–18 months and regular follow-up for up to 2 years
US: Pragmatic lifestyle programmes—Counselling, 
coaching and extended support relating to diet and 
physical activity for at least 3 months provided by 
trained staff in clinical or community settings
ADA: Intensive diet and physical activity behavioural 
counselling programme adhering to the tenets of the 
Diabetes Prevention Programme targeting a loss of 7% 
of body weight and an increasing moderate-intensity 
physical activity (such as brisk walking) to at least 
150 min/week
IFG, impaired fasting glucose; IGT, impaired glucose tolerance. 
Sources: ADA: Standards of Medical Care in Diabetes,9 UK: NICE guidance,88 USA: Community Preventative Services Task Force 
recommendations.21
Some studies may be included in more than one category, for example, if the study took place across multiple countries or used multiple 
diagnostic tests.
of 0.59 and 0.64. And a meta-analysis of pragmatic lifestyle 
interventions39 excluding large trials showed a relative risk 
of 0.74. The higher the relative risk, the less the effect of the 
intervention; therefore, these recent meta-analyses suggest 
that models based on DPP or DPS trial data will overstate 
the impact of interventions.
Key uncertainties regarding modelling assumptions
First, uncertainty remains over the extent to which the 
reduction in diabetes incidence persists once the interven-
tion has ended. Studies included in this review made a wide 
range of assumptions on this point, ranging from no effect 
after the intervention ended to effects persisting until the 
participant developed type 2 diabetes or died. One recent 
meta-analysis37 showed relative risks of 0.80 at up to 20 years 
follow-up. However, this analysis includes predominantly 
the large trials (USDPP, Finnish DPS lifestyle programme 
and Da Qing) as long-term follow-up data are not avail-
able on community-based translational studies. Therefore, 
this relative risk likely overstates the long-term benefits of 
interventions outside the trial context. Second, uncertainty 
persists over the percentage of people that fail to enrol in 
lifestyle interventions following screening. Reflecting this 
uncertainty, five studies included in this review assumed 
100% enrolment, two assumed between 50% and 99% and 
five assumed <50% enrolment. A recent systematic review87 
found that enrolment in interventions varies widely (from 
0.28% to 100%) depending on method of communication, 
setting and type of intervention. Finally, based on included 
studies, the relationship between the type of pre-diabetes 
and cost-effectiveness of the study is unclear. A factor which 
may be important given the differences in relative risk 
reductions illustrated by our meta-analysis.
DIscussIOn
Principal findings
This systematic review of economic evaluations of diabetes 
prevention programmes has produced seven major find-
ings. First, that numerous economic evaluations have 
been undertaken in 15 different countries and produced 
diverse results due to differences in model structure and 
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parameter values and to differences in health systems, types 
of pre-diabetes and types of lifestyle interventions included. 
Second, that the majority of evaluations relate to intensive 
trial-based interventions in populations in high-income 
countries identified with the oral glucose tolerance test. 
Third, that with these caveats in mind, both metformin and 
lifestyle interventions in people with pre-diabetes appear to 
be cost effective but not cost saving despite their impact on 
reducing diabetes incidence, with median ICERs of £8428/
QALY and £7490/QALY, respectively. To place this figure in 
context, smoking cessation services are estimated by NICE 
to have ICERs ranging from cost saving to £984/QALY90 and 
breast cancer screening is estimated to have an ICER of £20 
800/QALY by the UK Panel on Breast Cancer Screening.91 
The fact that diabetes prevention programmes are not cost 
saving is not due solely to the issue of discounting, as three 
studies40 54 62 report undiscounted cost-effectiveness ratios 
with only one of those appearing cost saving. Fourth, that 
metformin and lifestyle programmes appear equally cost 
effective when only the costs of the health system are taken 
into account, but metformin is more cost effective when 
costs of participants’ time (participating in and travelling to 
programme activities) are taken into account. Fifth, screen-
ing-plus-intervention programmes were less cost effective 
on average than intervention-only programmes. But both 
approaches were associated with a wide range of cost-ef-
fectiveness ratios and the population benefit of screening 
in identifying people with previously undiagnosed pre-dia-
betes is not taken into account in a cost-effectiveness calcu-
lation. Sixth, there is insufficient evidence to deduce what 
intensity, duration or format or lifestyle programmes are 
more cost effective than others. Finally, programmes that 
evaluated costs and benefits over ≥25 years were more cost 
effective than those that looked at ≤10 years.
Implications for policymakers
Both the type of pre-diabetes and the type of lifestyle 
programme have a substantial impact on the number of 
cases of diabetes that are delayed or prevented. Guidance 
in the UK and the USA advocate lower-intensity 'prag-
matic' lifestyle programmes and there is a small amount 
of evidence that these are cost effective. In light of recent 
meta-analyses, historical studies are likely overstating treat-
ment effects and uncertainty over duration of impact 
limits accurate long-term modelling. Guidance in the UK 
advocates the use of fasting plasma glucose or HbA1c in 
identifying people with pre-diabetes. There is currently 
insufficient data to conclude that interventions in people 
identified solely with HbA1c are cost effective, and no 
randomised controlled trials with HbA1c as the inclusion 
criteria to enable estimation of treatment effects. There is 
insufficient evidence to suggest that metformin is more cost 
effective than lifestyle programmes.
Policymakers need to make decisions even when all the 
evidence is not available, as is the case with the English 
national diabetes prevention programme (Healthier You: 
The NHS DPP)22 which provides low-intensity lifestyle 
programmes to people with IFG and or high HbA1c. In this 
case, rigorous evaluation alongside policy implementation 
could add to the evidence base, examining (1) what reduc-
tion in relative risk is associated with a large-scale imple-
mentation of a low-intensity lifestyle programme? (2) how 
does this reduction in risk attenuate over time? (3) how 
does reduction in relative risk differ by type of pre-diabetes?
In addition to these considerations of cost-effective-
ness, policymakers may need to balance impact on health 
budgets, incident cases of diabetes and equity of healthcare 
provision. In the few studies where these were modelled, 
budget impact was moderate (prevention programmes 
required 0.13%–0.2% of respective countries total health-
care budget), financial payoffs were delayed (net expendi-
ture on treatment and prevention of diabetes only declined 
after 9–14 years) and impact on incident cases of diabetes 
was limited (0.1%–1.6% reduction in incident cases). This 
suggests that other avenues to reducing incident cases of 
diabetes will need to be explored if substantial inroads are 
to be made in controlling the diabetes ‘epidemic’. These 
may include population-wide measures to address obesity, a 
primary determinant of progression to type 2 diabetes in a 
person with pre-diabetes.92
comparison with previous systematic reviews
Our findings confirm those of previous systematic reviews 
which have shown that lifestyle interventions are gener-
ally cost effective, but with a wide range of cost-effective-
ness ratios, reflecting heterogeneity of interventions, 
target populations and modelling approaches. They have 
shown that lifestyle interventions appear more cost effec-
tive if group, rather than individual sessions, are provided 
and a long time horizon is adopted for analysis. They 
have raised the issue of the limited number of studies in 
low-income andmiddle-income countries, the concern 
that real-life implementation of programmes will be less 
effective than trial-based interventions, and the uncer-
tainty that persists regarding long-term efficacy of these 
interventions. This review has added to previous work 
in three key areas: evaluation of metformin, comparison 
of screening-plus-intervention against intervention-only 
studies and consideration of the relevance and credibility 
of studies for decision makers.
suggestIOns fOr further reseArch
This study has identified three areas where further research 
would be beneficial. First, developing an understanding of 
how people with different types of pre-diabetes respond to 
interventions and the subsequent cost-effectiveness profiles 
for different diagnostic-treatment combinations. This could 
be undertaken in both modelling studies, using recent 
evidence from meta-analyses, or retrospective analysis of 
existing trial data where different types of pre-diabetes 
may coexist (eg, IGT and HbA1c, IGT and IFG or IGT-only 
participants). Second, long-term follow-up studies of prag-
matic lifestyle intervention programmes are important to 
understand the duration of impact on diabetes incidence 
following cessation of the intervention; uncertainty in this 
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area limits the accuracy of long-term modelling studies. 
Finally, consideration of the role of broader social and envi-
ronmental programmes (eg, sugar tax, increasing active 
travel) on diabetes incidence will be important as, based on 
studies in this review, individual lifestyle programmes and 
metformin are unlikely to be sufficient to address the vast 
majority of incident cases of diabetes.
cOncLusIOns
National diabetes prevention guidance in the UK and USA 
advocates pragmatic lifestyle programmes (<3 years in dura-
tion), and in the UK the use of HbA1c or fasting plasma 
glucose is recommended for diagnosing pre-diabetes. 
However, the majority of cost-effectiveness studies relate to 
a different definition of pre-diabetes and a higher inten-
sity of intervention, which limits the direct applicability of 
findings. In the few studies that evaluated other economic 
considerations, budget impact of prevention programmes 
was moderate, financial payoffs were delayed and impact 
on incident cases of diabetes was limited. There remains 
a need for long-term economic evaluation of programmes 
that reflect current policy and consideration of the role of 
broader social and environmental programmes on diabetes 
incidence.
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